Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 9;13:6762. doi: 10.1038/s41467-022-34434-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Representative images of immunofluorescence staining and quantification of the relative cardiomyocyte size treated with or without METTL14 overexpression or inhibition (n = 6 wells/group). Scale bar: 100 μm. b Representative images of immunofluorescence staining and quantification of the 5-ethynyl-2’-deoxyuridine (EdU) positive cardiomyocytes treated with or without METTL14 overexpression or inhibition (n = 4 wells/group). Scale bar: 100 μm. c Representative images of immunofluorescence staining and quantification of the Ki67 positive cardiomyocytes treated with or without METTL14 overexpression or inhibition (n = 4 wells/group). Scale bar: 100 μm. d Representative images of immunofluorescence staining and quantification of pHH3 positive cardiomyocytes treated with or without METTL14 overexpression or inhibition (n = 4 wells/group). Scale bar: 100 μm. e qPCR analysis of Anp, Bnp, β-Mhc mRNA expression levels in NRCMs treated with shMETTL14 or shScr (n = 6 wells /group). f Representative images of immunofluorescence staining and quantification of the TUNEL positive cardiomyocytes treated with shMETTL14 or shScr in OGD/R induced apoptosis model (n = 4 wells/group). Scale bar: 100 μm. g Representative western blot and statistical data of NRCMs apoptosis by detection of Bax, and Bcl2 in OGD/R induced apoptosis model treated with shMETTL14 or shScr (n = 6 wells/group). h Representative images of immunofluorescence staining and quantification of the TUNEL positive cardiomyocytes treated with METTL14 or Fugw in OGD/R induced apoptosis model (n = 4 wells/group). Scale bar: 100 μm. i Representative western blot and statistical data of NRCMs apoptosis by detection of Bax, and Bcl2 in OGD/R induced apoptosis model treated with METTL14 or Fugw (n = 6 wells/group). NRCM, neonatal rat cardiomyocyte. pHH3, phospho-Histone H3; shScr, Scramble short hairpin RNA; shMETTL14, METTL14 short hairpin RNA to knockdown METTL14; Fugw, control without METTL14 overexpression; METTL14 OE, METTL14 overexpression; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; OGD/R, oxygen-glucose deprivation/reperfusion. All data are expressed as means ± SD. ns, nonstatistically significant. a–e Independent-sample t-test, two-sided; f–i two-way ANOVA followed by Tukey’s post hoc test. Source data are provided as a Source Data file.